A modest debut for Ironwood’s new stock
First trading day was unconvincing, specialists say
It was one of the most anticipated debuts of a biotechnology stock in years. But shares of Ironwood Pharmaceuticals Inc. advanced only modestly yesterday on their first day of trading. (Full article: 562 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
